See LIPO-B dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
LIPO-B is a lipotropic injection formulation combining methionine, inositol, and choline (MIC) with B-complex vitamins, studied for its role in supporting fat metabolism, liver function, and energy production. It is commonly researched in the context of weight management protocols where enhanced lipid mobilization is a goal. This data captures the dose amounts, vial sizes, and diluent volumes researchers most commonly select when preparing LIPO-B injections.
LIPO-B is the methionine + inositol + choline (MIC) lipotropic injection blend extended with a B-vitamin profile distinct from LIPO-C — typically adding cyanocobalamin (B12) and a combination of B-complex vitamins (B1 thiamine, B2 riboflavin, B3 niacin, B5 pantothenic acid, B6 pyridoxine) to the MIC core. Where LIPO-C (covered separately on this site) typically includes a focused B12 + limited B-vitamin stack, LIPO-B is characterized by a broader B-vitamin complement. The mechanistic logic is identical to LIPO-C: methionine and choline serve as methyl donors and phosphatidylcholine precursors critical for hepatic very-low-density lipoprotein (VLDL) packaging and triglyceride export from the liver, while inositol contributes to phosphoinositide signaling and lipid trafficking.
LIPO-B (also called MIC injection) is a compounding-pharmacy injectable combining the methyl-donor amino acid methionine, the lipotropic factor inositol, the methyl-donor choline, and a B-complex (typically B1, B2, B3, B5, B6, B12 in varying proportions across compounding-pharmacy formulations). It is marketed for weight-loss support and lipid metabolism, almost exclusively from compounding pharmacies and weight-loss clinics — there is no FDA-approved fixed-combination LIPO-B drug product.
The "lipotropic" rationale is that methionine, inositol, and choline support hepatic fat metabolism by donating methyl groups for phosphatidylcholine synthesis and very-low-density-lipoprotein (VLDL) assembly, theoretically supporting the export of fat from the liver. The B-complex components support general energy metabolism. **The combined-product weight-loss mechanism is largely extrapolated from the individual nutrient pharmacology and from compounding-pharmacy marketing rather than from controlled clinical trials of the specific formulation.**
No registered controlled clinical trial has evaluated a specific LIPO-B / MIC injection formulation for weight loss as a primary outcome. Published controlled data on the individual components is moderate (choline and methionine in non-alcoholic fatty liver disease, vitamin B12 deficiency replacement, etc.), but the weight-loss claim driving consumer use of LIPO-B is not supported by Phase 2/3 evidence specific to the injectable combination.
LIPO-B has a reported half-life of varies by component, and the dose intervals researchers model most often fall around weekly. A lipotropic blend (methionine, inositol, choline, B12) with no single half-life — the B-vitamin component is retained while the lipotropics clear faster, so the weekly shot is a top-up rather than a steady-state drug. It is catalogued under Weight Loss on WPA.
20 LIPO-B reconstitution calculations have been logged by the WPA community. The most common dose entered is 1mg (7 calculations). The most common bacteriostatic water volume is 10mL. The most popular vial size is 10mg (11 sessions). The most common dosing frequency is once weekly (2 logged protocols), followed by 2x/week (1).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.